TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10172792
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid 500/125 mg 3 times daily for 10 days
Study: 26387117
Drug: Contact force
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact force (CF)‐guided ablation with a target CF of 20 g
Study: 22307382
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression therapy (3 h daily for 3 months)
Study: 22307382
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IPC therapy)
Study: 3057036
Drug: diltiazem (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem (360 mg/day)
Study: 29749262
Drug: Oxazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (10 mg every night)
Study: 26912554
Drug: AST-120 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (6 g in three divided doses per day)
Study: 26912554
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard conventional treatment)
Study: 10051494
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg orally once daily for 52 weeks
Study: 15131468
Drug: Lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine treatment
Study: 2147377
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate 20 mg once daily, increased to 40 mg once daily in 14 patients, with 12.5 mg hydrochlorothiazide added in 5 patients.
Study: 2147377
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 weeks) followed by enalapril maleate treatment.
Study: 31425504
Drug: L-5-methyltetrahydrofolate (10.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-methyltetrahydrofolate (10.4 μg/100 ml)
Study: 31425504
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (10.0 μg/100 ml)
Study: 28574779
Drug: Higher-dose trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose trastuzumab (HD) 10 mg/kg every 3 weeks
Study: 28574779
Drug: Standard-of-care (SoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SoC) trastuzumab 6 mg/kg every 3 weeks
Study: 9272404
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ibuprofen
Study: 12468609
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of dried mango with 5 g of fat, 5 d/wk for 4 mo
Study: 12468609
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of dried mango without fat, 5 d/wk for 4 mo
Study: 12468609
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule at baseline
Study: 9618753
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) treatment, cumulative 3.5 mg
Study: 9098473
Drug: Pellet-Swim-up (SU)
Normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pellet-Swim-up (SU) treatment
Study: 9098473
Drug: Centrifugation on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrifugation on Discontinuous Percoll Gradient (MP) treatment
Study: 31752000
Drug: Standard level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard level of 22 ± 1 mEq/L (Control)
Study: 25345731
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion relieving pain
Study: 21895745
Drug: Seasonal trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal trivalent influenza vaccine followed by two doses of pandemic H1N1 2009 vaccine (Group 1)
Study: 21895745
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of pandemic H1N1 2009 vaccine followed by simultaneous vaccination of seasonal trivalent vaccine and second dose of pandemic H1N1 2009 vaccine (Group 2)
Study: 28956169
Drug: Thermal mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal mineral water treatment (n=26)
Study: 24793941
Drug: 4 Pillars
Normalized name: BACCHARIS PILULARIS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 Pillars Toolkit and early vaccine supplies
Study: 20618338
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m2 + Tanespimycin 50 mg/m2
Study: 843177
Drug: Major role
Approvals — FDA: no, EMA: no, PMDA: no
Description: Major role therapy (MRT)
Study: 843177
Drug: Regular medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular medication adherence support (e.g., visiting nurse, long-acting medication)
Study: 22696580
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for partial seizures
Study: 18842771
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg dairy calcium supplementation per day for 5 weeks
Study: 8908381
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.7 g/day eicosapentaenoic plus docosahexaenoic acid for 2 months, then 1.7 g/day for 4 more months)
Study: 6613136
Drug: Fibrinogen cryoprecipitate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen cryoprecipitate, thrombin solution, and factor XIII concentrate used for gluing in suprapubic transvesical prostatectomy
Study: 16236038
Drug: Fluvoxamine (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (four doses of 100 mg over 2 days)
Study: 16236038
Drug: Caffeine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (single 250 mg dose)
Study: 16236038
Drug: Fluvoxamine (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (four doses of 100 mg over 2 days) + Caffeine (single 250 mg dose)
Study: 2868030
Drug: Diltiazem, 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 240 mg/day
Study: 2152233
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 to 240 mg/day)
Study: 18511533
Drug: Comprehensive pragmatic
Normalized name: chloroxylenol / pramoxine hydrochloride Otic Solution [Pramotic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive pragmatic manual therapy programme including specific corticosteroid injections (n = 89)
Study: 10674267
Drug: Post-treatment follow-up
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment follow-up after 3 months
Study: 22791944
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (G)
Study: 31281061
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (fluticasone furoate-umeclidinium-vilanterol)
Study: 31281061
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (fluticasone furoate-vilanterol)
Study: 28757912
Drug: Protective lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective lung ventilation (6 mL/kg tidal volume and 10 cm H2O PEEP)
Study: 9207389
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg oxamniquine
Study: 21176950
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg praziquantel
Study: 2692093
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol
Study: 22624993
Drug: Antioxidant cream
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant cream
Study: 24945268
Drug: Barrier cream
Normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier cream
Study: 27378550
Drug: Amisulpride (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (400 mg)
Study: 20530013
Drug: Pramipexole dihydrochloride
Normalized name: Pramipexole Dihydrochloride
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramipexole dihydrochloride (0.5 mg)
Study: 16841679
Drug: Neiyi pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neiyi pill (NP)
Study: 16841679
Drug: Neiyi pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neiyi pill (NP) and Neiyi enema (NE)
Study: 14520726
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alfa (Pulmozyme) treatment
Study: 3855724
Drug: Methyldopa (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (3.5 mg/kg) with sodium sulfate (13.25 mg/kg)
Study: 3855724
Drug: Methyldopa (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (3.5 mg/kg) alone
Study: 29737100
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tenofovir disoproxil fumarate tablets under high-fat diet conditions
Study: 22341736
Drug: SYNERGY half
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNERGY half dose
Study: 16338260
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg daily for 8 weeks
Study: 2756307
Drug: Iodine solution
Normalized name: Iodine solution
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine solution (2%)
Study: 2756307
Drug: Barium suspension
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barium suspension (1.5%)
Study: 22565655
Drug: Exercise programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise programme aimed at improving handgrip (HS) and pinch strengths (PS) as well as motor coordination of the hand, 20 sessions, twice a week, at-home exercises
Study: 22565655
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for hands (control)
Study: 15589004
Drug: Trandolapril 4
Normalized name: trandolapril 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 4 mg/day
Study: 2988589
Drug: Enalapril 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 40 mg/day
Study: 9399748
Drug: High-dose histamine-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose histamine-2 receptor antagonist (H2RA) strategy
Study: 9399748
Drug: Standard-dose histamine-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose histamine-2 receptor antagonist (H2RA) strategy
Study: 1287614
Drug: Cefaclor AF
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor AF 375 mg twice daily
Study: 2992839
Drug: Minocromil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocromil (4 mg)
Study: 30833367
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) plus lifestyle counseling
Study: 29231587
Drug: Bobath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bobath therapy
Study: 23263355
Drug: idebenone (Catena;
Approvals — FDA: no, EMA: no, PMDA: no
Description: idebenone (Catena; 900 mg/d)
Study: 17070426
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor antagonist therapy in control group
Study: 12668364
Drug: Ziprasidone (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (40-80 mg twice daily)
Study: 10743446
Drug: Ketamine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (bolus 0.1 mg kg‐1 over 10 min followed by infusion of 7 micrograms kg‐1 min‐1)
Study: 10743446
Drug: Lidocaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (5 mg kg‐1)
Study: 22528506
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution (50 mg)
Study: 22403324
Drug: Pyronaridine/Artesunate (PA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyronaridine/Artesunate (PA) with Ritonavir (100 mg twice daily for 17 days, PA administered on Days 8-10)
Study: 20353110
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Routine treatments in western medicine including gastrointestinal decompression, parenteral nutrition, anti-infection, supportive therapy.
Study: 20353110
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Electroacupuncture in Zusanli (ST 36), Shangjuxu (ST 37) in addition to Group A treatments.
Study: 10738013
Drug: MDI-S (metered-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI-S (metered-dose inhaler with spacer)
Study: 28283823
Drug: Freeze-dried blueberry
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried blueberry (24 g/day, equivalent to 1 cup of fresh blueberries) for 90 days
Study: 24793893
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) 3 g
Study: 22817667
Drug: Erlotinib followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib followed by chemotherapy after progression
Study: 22817667
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by erlotinib after progression
Study: 11895146
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with fish oil (0.2 g/kg body weight per day) plus soybean oil (1.0 g/kg per day)
Study: 11895146
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil (1.2 g/kg per day)
Study: 9751068
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg salbutamol via metered-dose inhalers (MDIs)
Study: 27152103
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral administration of 250 mL of mangosteen-based juice (305 mg of α-mangostin and 278 mg of hydroxycitric acid)
Study: 21619670
Drug: Glucose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (50 g)
Study: 12932433
Drug: Placebo (27.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (27.3 mg saccharin)
Study: 9097873
Drug: m‐CPP (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐CPP (0.5 mg/kg of body weight)
Study: 8040669
Drug: High-dose IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IL-2 (720,000 IU/kg)
Study: 28807019
Drug: Antenatal syphilis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal syphilis screening and treatment intervention (details on dosage and duration not available)
Study: 2675669
Drug: Propylene glycol
Normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propylene glycol formulation of etomidate (Hypnomidate)
Study: 1253812
Drug: Fructose administered
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose administered simultaneously with ethanol
Study: 1253812
Drug: Glucose administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose administered simultaneously with ethanol
Study: 1253812
Drug: Glucose administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose administered 12 hours later during the hangover period
Study: 17881390
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) treatment
Study: 17111195
Drug: Thrombolysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis with ultra-high dose streptokinase (n = 8)
Study: 15461606
Drug: Parietaria pollen
Normalized name: Parietaria officinalis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parietaria pollen vaccine
Study: 15317270
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo injections
Study: 10668686
Drug: Unopposed conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unopposed conjugated equine estrogens (1.25 mg/day) for 16 weeks
Study: 9061102
Drug: Oxycodone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (20 mg or 40 mg oral controlled-release tablet)
Study: 3021324
Drug: Sulpiride (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (600 mg intramuscularly in a single administration, followed by 200 mg 3 times per day from days 2-21, then 100 mg and 50 mg 3 times per day on days 22-25 and 26-29, respectively)
Study: 20188175
Drug: M01ZH09 (typhoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: M01ZH09 (typhoid vaccine)
Study: 6357036
Drug: Topical povidone‐iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical povidone‐iodine spray in addition to a single dose of intravenous metronidazole
Study: 6357036
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intravenous metronidazole
Study: 25902655
Drug: Perindopril 5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 5‐10 mg/day + Indapamide retard 1.5 mg/day (P+I)
Study: 25902655
Drug: Perindopril 5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 5‐10 mg/day + Hydrochlorothiazide 25 mg/day (P+HT)
Study: 15510982
Drug: rHuEPO (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (5000 U/day subcutaneously three times a week) until three weeks after chemotherapy completion in Groups 1, 2A, and 3A
Study: 16916538
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg cocaine
Study: 3605793
Drug: epinephrine by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine by subcutaneous injection
Study: 15975493
Drug: Control plus
Normalized name: SODIUM FLUORIDE 2.4 mg in 1 g DENTAL GEL, DENTIFRICE [AIM TARTAR CONTROL Plus Mouthwash and Whitening]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control plus 1000 mg of S. oblonga extract (S)
Study: 11834946
Drug: ARV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARV therapy (ritonavir)
Study: 11834946
Drug: ARV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARV therapy (zidovudine)
Study: 11834946
Drug: ARV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARV therapy
Study: 1519784
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl 50 micrograms.h‐1
Study: 7747844
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl 75 micrograms.h‐1
Study: 11764012
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg triazolam
Study: 22276954
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone
Study: 28793993
Drug: Heparin 100
Normalized name: heparin 100 units/mL injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 100 IE/mL
Study: 28793993
Drug: Taurolidine-citrate-heparin lock
Normalized name: heparin / taurolidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolidine-citrate-heparin lock
Study: 25749825
Drug: Intrathecal liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal liposomal cytarabine (50 mg)
Study: 25749825
Drug: Intrathecal triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal triple therapy
Study: 23406078
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravenous hydromorphone
Study: 16083782
Drug: 250 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 microg of oral roflumilast
Study: 16083782
Drug: 500 microg
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg of oral roflumilast
Study: 17656354
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with morphine
Study: 6752250
Drug: Psychotherapy (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy (weekly 30-50 minutes sessions of interpersonal psychotherapy)
Study: 6752250
Drug: Pharmacotherapy (random
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (random assignment to either alprazolam, imipramine, or pill-placebo for six weeks)
Study: 6752250
Drug: Community publicity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community publicity regarding psychotherapy treatment program
Study: 20418510
Drug: Eltrombopag 100
Normalized name: eltrombopag 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 100 mg once daily
Study: 20418510
Drug: Eltrombopag 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 150 mg once daily
Study: 20418510
Drug: Eltrombopag 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 200 mg once daily
Study: 20418510
Drug: Eltrombopag (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (all doses)
Study: 7722161
Drug: Physician-targeted educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-targeted educational program on inhaled therapy (45 minutes, one-on-two teaching sessions)
Study: 25162603
Drug: Oxycodone solution
Normalized name: oxycodone Injectable Solution
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone solution
Study: 17645249
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at Ganshu (BL 18), Shenshu (BL 23), Xinshu (BL 15), once daily.
Study: 17645249
Drug: Fluoxetine hydrochloride,
Normalized name: FLUoxetine Hydrochloride, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride, 20 mg, once daily (control group).
Study: 24807604
Drug: CO2-releasing suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2-releasing suppository
Study: 7643191
Drug: 2.5 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 percent Lidocaine ointment